- cafead Jan 29, 2024 at 11:32: AM
via With last week seeing back-to-back oversized biotech IPOs to kick off the new year, it’s no surprise that Fractyl Health is now kicking its own offering plans up a gear.
The Lexington, Mass.-based biotech announced in December 2023 that a potential IPO could be near, with the proceeds earmarked to complete a 1,000-person study of an endoscopic procedure, called Revita, to back up a planned U.S. approval application. Funds would also go towards continued preclinical development of a GLP-1-based pancreatic gene therapy Rejuva.
article source
The Lexington, Mass.-based biotech announced in December 2023 that a potential IPO could be near, with the proceeds earmarked to complete a 1,000-person study of an endoscopic procedure, called Revita, to back up a planned U.S. approval application. Funds would also go towards continued preclinical development of a GLP-1-based pancreatic gene therapy Rejuva.
article source